Accentia Biopharmace (ABPI) 0.0015 $ABPI
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Accentia Biopharmaceuticals, Inc. and Certain Officers and Biovest International, Inc. - ABPI and BVTI
PR Newswire - Tue Aug 06, 4:26PM CDT
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Accentia Biopharmaceuticals, Inc. ("Accentia" or the "Company"
(Pink Sheets: ABPI) and certain of its officers and Biovest International, Inc. ("Biovest" (OTCQB: BVTI), a majority-owned subsidiary of Accentia. The class action, filed in United States District Court, Middle District of Florida, and docketed under 13-CV-2033-T24-AEP, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Accentia between July 26, 2008 and August 14, 2012 both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Accentia Biopharmaceuticals, Inc. and Certain Officers and Biovest International, Inc. - ABPI and BVTI
PR Newswire - Tue Aug 06, 4:26PM CDT
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Accentia Biopharmaceuticals, Inc. ("Accentia" or the "Company"
(Pink Sheets: ABPI) and certain of its officers and Biovest International, Inc. ("Biovest" (OTCQB: BVTI), a majority-owned subsidiary of Accentia. The class action, filed in United States District Court, Middle District of Florida, and docketed under 13-CV-2033-T24-AEP, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Accentia between July 26, 2008 and August 14, 2012 both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. 
